Apeiron Investment Group is a family office and asset management firm that focuses on investments in biotechnology, deep tech, life sciences, and real estate companies. It completes deals across the entire lifecycle and balance sheet of a company, from non-listed seed/start-up investments to larger-scale restructuring and special situations deals. Apeiron's current portfolio encompasses more than 80 high-growth tech companies in Europe, the United States, and Asia.
When Apeiron sees major trends and structural changes happening in one of its core sectors, it regularly sets up and invests in platform companies in order to make concentrated and focused bets and acquisitions.
Apeiron takes active minority stakes in listed companies mainly through IPOs & SPACs, but sometimes also later in a company’s life cycle.
Via Elevat3, Apeiron takes active minority stakes from Series-A to Pre-IPO mainly in Europe/Germany, with Peter Thiel’s Founders Fund as a strategic partner.
With the Presight Capital Fund Series, Apeiron follows a very flexible, diversified approach, investing in the most ambitious founders globally at any stage, together with leading VCs.
Apeiron has been a major driver of the long-deserved ‘psychedelic renaissance’ as a potential treatment for various mental health issues.
Apeiron tries to combine Germany´s strength in innovation and technology with US-style entrepreneurship and company-building thinking when investing in European spaceTech companies.
Apeiron invests globally in hedge funds and venture capital funds. It takes an entrepreneurial approach and is open to first-time funds/managers, seeding funds, etc.